Currently out of the existing stock ratings of Navin Jacob, 20 are a HOLD (37.04%), 32 are a BUY (59.26%), 2 are a SELL (3.7%).

Navin Jacob

Work Performance Price Targets & Ratings Chart

Analyst Navin Jacob, carries an average stock price target met ratio of 71.76% that have a potential upside of 24.37% achieved within 561 days. Previously, Navin Jacob worked at UBS, DEUTSCHE BANK.

Navin Jacob’s has documented 112 price targets and ratings displayed on 19 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on RAPT, RAPT Therapeutics at 28-Mar-2022.

Wall Street Analyst Navin Jacob

Analyst best performing recommendations are on MDGL (MADRIGAL PHARMACEUTICALS).
The best stock recommendation documented was for MDGL (MADRIGAL PHARMACEUTICALS) at 1/23/2019. The price target of $119 was fulfilled within 14 days with a profit of $10.04 (9.21%) receiving and performance score of 6.58.

Average potential price target upside

of $45.9 (78.08%) on ICPT (INTERCEPT PHARMACEUTICALS).
of $32.32 (21.19%) on VRTX (VERTEX PHARMACEUTICALS).
of $29.49 (42.08%) on ABBV (ABBVIE).

ABBV AbbVie LLY Eli Lilly and Company RPRX Royalty Pharma Plc AGN Allergan plc ICPT Intercept Pharmaceuticals MYL Viatris TEVA Teva Pharma Industries Ltd ADR ZTS Zoetis MRK Merck mpany CELG Celgene REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals APLT Applied Therapeutics ELAN Elanco Animal Health MDGL Madrigal Pharmaceuticals VTRS Viatris GILD Gilead Sciences PFE Pfizer RAPT RAPT Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gary Nachman (RAYMOND JAMES)